Notable Labs, Ltd., a clinical-stage platform therapeutics company, develops predictive medicines for patients with cancer. The company, through its proprietary Predictive Medicines Platform (PMP), bio-simulates a patient's cancer treatment and predicts whether patient will clinically respond to their actual treatment. Its PMP is designed to identify and select patients expected to be clinically responsive prior to the initiation of their treatment and enable fast-track therapeutic development in this patient population. The company's lead product is Volasertib, a polo like kinase 1 inhibitor to induce cell cycle arrest and apoptosis in various cancer cells. It is also developing two candidate predictive medicines and clinical-stage candidates for development in platform-predicted responders with acute myeloid leukemia. The company is based in Foster City, California. On October 13, 2024, Notable Labs, Ltd. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.
Часто задаваемые вопросы
В каком секторе работает NTBLQ (NTBLQ)?
NTBLQ относится к сектору Прочее.
Какова текущая цена акций NTBLQ (NTBLQ)?
По последним данным, цена акций NTBLQ составляет 0,00 $, предыдущее закрытие — 0,00 $.
Выплачивает ли NTBLQ (NTBLQ) дивиденды?
Нет, NTBLQ не выплачивает дивиденды.
Какой бета-коэффициент (волатильность) у NTBLQ (NTBLQ)?
У компании NTBLQ бета 29.641, что свидетельствует о крайне высокой волатильности по сравнению с рынком
